Synthace

The UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.

Company Growth (employees)

Type

Private

London, GB

Founded

2011

Size (employees)

29 (est)+4%

Website

synthace.com

Synthace was founded in 2011 and is headquartered in London, GB

Key People at Synthace

Tim Fell

CEO

Christopher Grant Ward

Co-Founder

Markus Gershater

CSO

Sean Ward

Founder and CTO

Synthace Office Locations

Synthace has an office in London

London, GB (HQ)

2 Royal College St

Synthace Data and Metrics

Summary Metrics

Founding Date	2011
Total Funding	$2.9 m
Latest funding size	$1.9 m
Time since last funding	almost 4 years
Investors	Sofinnova Partners, SOSV, Sami Mikati, Keith Willey, David Lucas, Michail Eleftheriou, Sharaf Yamani, John Anthony Knight

Synthace's latest funding round in September 2013 was reported to be $1.9 m. In total, Synthace has raised $2.9 m

Synthace Financial Metrics

Summary

GBP

Balance Sheet

GBP	FY, 2014	FY, 2015	FY, 2016
Cash	321.7 k	1.5 m	245 k
Accounts Receivable	159.9 k	73.2 k	401.8 k
Current Assets	481.6 k	1.6 m	646.8 k
PP&E	298.8 k	200.5 k	265.6 k
Total Assets	780.4 k	1.8 m	912.3 k
Accounts Payable	183.5 k	103 k	154.8 k
Current Liabilities	183.5 k	103 k	154.8 k
Total Liabilities	183.5 k	103 k	154.8 k
Total Equity	596.9 k	1.7 m	757.5 k
Financial Leverage	1.3 x	1.1 x	1.2 x